Skip to content Skip to footer
Eupraxia Pharmaceuticals (EPRX) delivered an impressive third quarter for 2025, underpinned by breakthrough clinical data, robust financial positioning, and a clearer trajectory toward commercial success. The company’s RESOLVE trial in eosinophilic esophagitis (EoE) demonstrated sustained clinical remission and long-lasting improvements in tissue…
Geoffrey Hinton, the “Godfather of AI,” is sounding an alarm that could shatter Silicon Valley’s favorite narrative: the notion that artificial intelligence, like a well-trained dog, will sit, stay, and obey. Fresh off his Nobel Prize win for machine learning, Hinton spends…